City

Condition

PARP Inhibitor for Esophageal Squamous Cell Carcinoma (1)

Overall Status

Not yet recruiting (1)

Phase

phase 2 (1)

Sponsor

Chongqing University Cancer Hospital (1)

Collaborator

Intervention

fluzoparib monotherapy or fluzoparib with camrelizumab(only non-small cell lung cancer arm) ,or fluzoparib combined with capecitabine (only rectal cancer arm)) (1)

Study Documents

Intervention Type

drug (1)

Funder Type

Other (1)

Study Type

Interventional (1)

parp inhibitor for esophageal squamous cell carcinoma

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

PARP Inhibitor for Esophageal Squamous Cell Carcinoma Trial (Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only

Not yet recruiting

PARP Inhibitor for Esophageal Squamous Cell Carcinoma

Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))

(no location specified)

Sep 24, 2023